Medical Oncology

Uzm. Dr. Selver Işık

Doctor and researcher Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi İstanbul
Carcinoma, Renal CellKidney NeoplasmsLung NeoplasmsCarcinoma, Non-Small-Cell LungBrain NeoplasmsStomach NeoplasmsBone NeoplasmsAdenocarcinomaColonic NeoplasmsLiver NeoplasmsCarcinoma, HepatocellularBiliary Tract NeoplasmsSarcomaSoft Tissue Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Carcinoma, Renal Cell 9 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Kidney Neoplasms 9 publications
  • Lung Neoplasms 6 publications
  • Carcinoma, Non-Small-Cell Lung 5 publications
  • Brain Neoplasms 3 publications
  • Stomach Neoplasms 3 publications
  • Bone Neoplasms 3 publications
  • Adenocarcinoma 3 publications
  • Colonic Neoplasms 3 publications
  • Liver Neoplasms 3 publications
  • Carcinoma, Hepatocellular 2 publications
  • Biliary Tract Neoplasms 2 publications
  • Sarcoma 2 publications
  • Soft Tissue Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionMarmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workCarcinoma, Renal CellExtracted from 9 publications · Model version —From source
  • Publications79 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-2726-1740ORCIDFrom source
  • Last synchronised5 November 2026 10:37https://marmaraeah.saglik.gov.tr/TR-1393453/doktorlarimiz.html#selver-isiksaglik.gov.tr

Scientific work

Publications on Carcinoma, Renal Cell

79 publications

  1. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15725-9 PMID 41691201 Open-access full textSource: OpenAlex

  2. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

    Clinical & Translational Oncology, 2026

    DOI 10.1007/s12094-026-04494-3 PMID 42400766 Source: OpenAlex

  3. Determinants of survival after neoadjuvant chemotherapy in resectable gastric cancer: adjuvant dose intensity, radiotherapy, and pathologic response

    Expert Review of Anticancer Therapy, 2026

    DOI 10.1080/14737140.2026.2657911 PMID 41950348 Source: OpenAlex

  4. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

    Cancers, 2026

    DOI 10.3390/cancers18132127 PMID 42449669 Open-access full textSource: OpenAlex

  5. Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16664-1 Open-access full textSource: OpenAlex

  6. Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15134901 PMID 42452362 Open-access full textSource: ORCID

  7. Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020798 PMID 41598735 Open-access full textSource: ORCID

  8. Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020890 PMID 41598826 2 citations (Europe PMC) Open-access full textSource: ORCID

  9. Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

    Medicina, 2026

    DOI 10.3390/medicina62030488 PMID 41901569 Open-access full textSource: OpenAlex

  10. Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group

    JCO Global Oncology, 2026

    DOI 10.1200/go-26-00317 PMID 42715501 Open-access full textSource: ORCID

View all 79 publications